Autoantibodies against the muscle acetylcholine receptor (AChR) play an essential role in the pathophysiology of autoimmune myasthenia gravis (MG). Their serum titers, however, vary considerably among patients. Our aim was to investigate whether their variation might be explained by genetic factors. Using different methods, we have obtained strong evidence for a threelocus association influencing autoantibody titers in MG patients with thymus hyperplasia or with a normal thymus. Two of the loci, one encoding the AChR a-subunit, the other encoding the a-chain of the class II antigen-presentation molecule, HLA-DQ, demonstrated interaction to determine high autoantibody titers. The third locus was associated with the 8.1 ancestral HLA haplotype. It exerted an additive effect and it is posutlated to have a nonantigen specific immunoregulatory function. Our study demonstrates for the first time that polymorphism of an autoantigen gene may quantitatively modify the immune response against it. Altogether, the data lend support to a three-gene model to explain autoantibody expression in a subset of MG patients.
Introduction
Acquired generalized myasthenia gravis (MG) provides a remarkable model for studying the mechanisms of antibody-mediated autoimmunity. [1] [2] [3] The main self-antigen in MG is the muscle acetylcholine receptor (AChR), a pentameric transmembrane complex that is made of four subunits, a 2 bde in adult muscle or a 2 bgd in the fetus. 4 In the majority (85%) of the patients, it is targeted by highly specific autoantibodies. 5, 6 Although other factors, notably the complement pathway, are necessary to produce the clinical symptoms, 7, 8 anti-AChR autoantibodies are a primary effector in MG, in addition to being an essential diagnostic tool, and understanding the mechanisms of their production and of their regulation is of substantial importance. 9 The thymus of MG patients is often abnormal and this plays an essential role in autoantibody production. 10, 11 It may show the presence of germinal centers containing autoantibody-producing B cells, an anomaly also known as thymus hyperplasia, or a malignant transformation, or thymoma. Thymus anomalies are also a major factor of clinical and biological heterogeneity of the disease. 12, 13 As is the case for most autoimmune diseases, MG has a complex genetic control. 14 The extended HLA-A1-B8-DR3 haloptype, also called the 8.1 ancestral haplotype, 15 has long been associated with the form of MG with thymus hyperplasia, 16 defining the MYAS1 locus. 17 Association with HLA, however, explains the genetic component of MG only partly. Among other genes, our laboratory has developed a particular interest in the genes encoding the self-antigen, the AChR, given its central role in MG pathogenesis. We notably investigated the CHRNA1 gene, which encodes the a-subunit, the target of most autoantibodies. 4 Using a microsatellite located in its first intron, we previously showed an association with MG of an allele of this microsatellite, designated HB*14, 18 a finding that was reproduced in different populations. 19 Remarkably, a synergistic association was also characterized between HB*14 and two HLA-linked gene alleles. 20 One was the class II DQA1*0101 allele while the other was in linkage disequilibrium with the 8.1 ancestral haplotype. To explain this pattern of association, we had proposed a three-locus working model. 20 In this model, an epitope of the AChR a-subunit would be presented to T lymphocytes or to their thymic precursors by an HLA-DQ molecule, whose a-chain is encoded by DQA1*0101. This presentation would perturb T-cell tolerization, leading to the emergence of auto-reactive lymphocytes. A nonantigen specific immunoregulatory locus associated with the 8.1 haplotype would then amplify this process.
In the present study, we have re-investigated the threelocus model, considering serum titers of anti-AChR autoantibodies as a quantitative endophenotype for MG. We also accounted for the heterogeneity of disease associated with thymus histopathology. The data reported provide strong support for the model. For the first time, they also demonstrate a polygenic control for a quantitative trait in a human autoimmune disease.
Results
Design of the analysis Effects of the genetic factors, including (i) the self-antigen CHRNA1 gene polymorphism, HB*14, (ii) the HLA class II allele, DQA1*0101 and (iii) the 8.1 ancestral haplotype, were investigated by an analysis of variance (ANOVA) to allow for testing multiple explanatory factors, whether independently or in combination. As the thymus histopathology is already known to influence anti-AChR antibody titers, 13 it was desirable to introduce it in the analysis. However, it is also closely correlated with the 8.1 ancestral haplotype, since patients with thymus hyperplasia and those with a normal thymus show a strong association with this haplotype. 17 This prevented a direct four-way analysis, testing the three genetic factors and thymus histopathology. Therefore, an influence of HB*14, DQA1*0101 and thymus histopathology was tested first. In a second part of the study, we sought confirmation of the findings by different methods and we performed a family-based association test and a casecontrol comparison.
Combined effect of HB*14 and DQA1*0101 with thymus histopathology on autoantibody titers A group of 480 French Caucasian patients with generalized MG was investigated. Their main features are shown in Table 1 . Only seropositive patients were included as the CHRNA1 gene was a candidate. The distribution of serum titers was fitted to a Gaussian curve by a logarithmic transformation. As explained just above, a three-factor ANOVA was conducted first to test the combined effect on autoantibodies of HB*14, DQA1*0101 and thymus histopathology. Main effects were observed for HB*14 (P ¼ 0.0094) and thymus histopathology (P ¼ 0.0031). In other words, these effects could be detected by themselves, independently of the other factors. DQA1*0101 had no effect alone but it interacted with HB*14 (P ¼ 0.029) and with thymus histopathology (P ¼ 0.013). Figure 1 provides a graphical representation of these effects. Table 2 shows the serum titers depending on the various combinations of the three factors. No significant variation in the means was observed among patients who were negative for DQA1*0101. In those who were positive, by contrast, the presence of HB*14 correlated with increased antiAChR autoantibody titers both in patients with thymus hyperplasia (six-fold: P ¼ 0.004) and in those with a normal thymus (12-fold: P ¼ 0.02), but not in those with a thymoma or in nonthymectomized patients.
Pooling the thymectomized non-thymoma patients increased the significance of the effect of HB*14 (mean7s.d. in the 39 HB*14À patients: 1.0370.87, and in the 13 HB*14 þ patients: 2.0370.85; P ¼ 0.0006). Altogether, the data indicated that interaction between HB*14 and an HLA class II gene correlates with increased autoantibody titers in MG patients with a normal or hyperplastic thymus. 
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Additive effect of the 8.1 ancestral haplotype on autoantibody titers In our patients with thymus hyperplasia or with a normal thymus, a strong association with the HLA DR3 marker has been demonstrated. 17 The HLA-DR3-B8 haplotype was also associated with increased titers of anti-AChR autoantibodies. 12 Owing to the strong linkage disequilibria across the HLA complex, it is suspected that an allele of a linked locus, rather than DR3 itself, is responsible for these associations. 21, 22 Regarding the titers of anti-AChR autoantibodies, work in progress from our laboratory points to an allele of a microsatellite marker in the central region of HLA, designated as TNFD*1, as explaining the variance of autoantibody titers better than DR3. The TNFD marker is located in the central region of HLA, in the third intron of the LST-1 gene, 650 kbp telomerically to HLA class II loci and 6 kbp centromerically to the TNF gene cluster ( Figure 2 ).
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A three-factor ANOVA was therefore performed to assess the effects of HB*14, DQA1*0101 and TNFD*1 on anti-AChR antibody titers in the 235 MG patients with a hyperplastic or a normal thymus. Figure 3 shows the graphical representation of the effects. Introducing TNFD*1 increased the significance of HB*14 (P ¼ 0.0016) and of its interaction term with DQA1*0101 (P ¼ 0.0041). The effect of TNFD*1 was also significant (P ¼ 0.0001), but it appeared to be additive rather than synergistic with HB*14 and DQA1*0101. Detailed data are shown in Table 3 . As previously, HB*14 was associated with a marked increase of mean titers of anti-AChR autoantibodies in the DQA1*0101-positive patients. This increase was five-fold in patients negative for TNFD*1 (P ¼ 0.07) and 18-fold for those positive for TNFD*1 (P ¼ 0.0006). Moreover, the eight patients who were positive for the three factors had the highest levels of anti-AChR autoantibodies (P ¼ 5 Â 10
À5
for their comparison to all other patients grouped). They were all women with thymus hyperplasia and an early onset of disease, before 40 years.
Altogether, the data confirmed the interaction between HB*14 and the HLA class II locus and disclosed an additive effect of a second HLA-linked locus that is associated with the 8.1 ancestral haplotype. Titers of autoantibodies (in nmol/l) were normalized by logarithmic transformation. 
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Unbalanced transmission of HB*14 parental alleles to DQA1*0101 þ patients Testing the transmission of parental HB*14 alleles to affected offspring, who were either positive or negative for DQA1*0101 provided an opportunity to check the consistency of the data obtained by ANOVA. Such family-based association tests are robust and notably are insensitive to population structure. The transmissiondisequilibrium test (TDT) was performed in 27 families with one DQA1*0101-positive child affected with MG and having thymus hyperplasia (n ¼ 17) or a normal thymus (n ¼ 10). For 20 patients, both parents could be genotyped. For three other patients, only mothers were available for genotyping. Altogether, 30 parents were heterozygous and thus potentially informative for TDT. As shown in Table 4 , the HB*14 allele was transmitted to seven children and untransmitted in one case (P ¼ 0.031). Transmission of other HB alleles was balanced. In addition, no distortion of HB*14 transmission was observed in 71 DQA1*0101-negative patients with thymus hyperplasia or with a normal thymus (data not shown).
Case-control study Finally, an association of the three genetic markers was tested by a case-control study comparing the unrelated 235 seropositive MG patients with thymus hyperplasia or with a normal thymus to a control group of 111 Caucasian subjects (Table 5) . A logistic regression model following that of ANOVA and including the three main factors and an interaction term between HB*14 and DQA1*0101 was considered. The only significant effect overall was associated with TNFD*1 (Odds ratio (OR), 3.85; 95% confidence interval (CI), 2.24-6.79, Po1 Â 10 À4 ), reflecting the strong association of the 8.1 haplotype in these patients. 17 However, when the 25% of patients with the highest autoantibody titers, corresponding to the upper quartile (477.8 nmol/l) and including 44 patients with a thymus hyperplasia and 15 patients with a normal thymus, was considered, the analysis disclosed a significant effect for the interaction between HB*14 and DQA1*0101 as well as for TNFD*1.
Discussion
Our first main and new finding is that the polymorphism of a gene encoding a self-antigen may quantitatively modify the amount of circulating antibodies against it in a human autoimmune disease. In this study, the HB*14 marker was a surrogate for CHRNA1. Our work in progress, based on an exhaustive analysis of the polymorphism of CHRNA1, indicates that HB*14 is also likely to be etiological (MG, in preparation). Regarding a potential mechanism explaining its effect on CHRNA1 expression, dinucleotide repeats of the poly-(CA) type like the HB microsatellite, can form alternative DNA structures, such as Z-DNA 24,25 and, as recently described in the rat nucleolin gene or in the human PIG3 gene, discrete variations in the number of repeats may modify transcriptional activity significantly. 26, 27 It remains to be explained how a change in CHRNA1 expression could cause a breakdown of self tolerance. This should be discussed in light of the association with the other two genetic factors.
Indeed, the second main outcome of our study has been the validation and the refinement of the three-locus model previously proposed. Both the ANOVA and the case-control study confirmed an involvement of the three genetic factors, with an interaction term between two of them. Moreover, the genetic effects were observed in thymectomized patients with thymus hyperplasia or a normal thymus, who are predominantly women with an early onset of disease and often high titers of anti-AChR autoantibodies. Conversely, nonthymectomized patients were not concerned by the genetic associations. This group of patients shows no correlation between the age at onset of disease and autoantibody titers (not shown) and is quite heterogeneous. Therefore, it might be useful to consider it separately in future studies.
The interaction term between the self-antigen polymorphism, HB*14, and the HLA class II allele, DQA1*0101, is consistent with a mechanism of breakdown of self-tolerance that involves antigen presentation. A primary mechanism of T-cell tolerance induction is the deletion of self-reactive T cells in the thymus. 
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Immature T cells encounter peptides derived from endogenous proteins bound to major-histocompatibility complex (MHC) molecules and expressed by thymic epithelial cells. 29 T cells with high-affinity receptors for these complexes undergo apoptosis, resulting in negative selection. Such induction of central tolerance requires the presence of autoantigen in sufficient amount in the thymus. Remarkably, the AChR has been shown to be expressed in thymic epithelial cells. 30 Therefore, a quantitative modification of its expression in these cells, such as a decrease, in the presence of HB*14, could result in failure of negative selection. Interestingly, non-HB*14 alleles might have an opposite effect on CHRNA1 thymic expression and therefore on tolerance induction towards AChR epitopes. This could explain why patients positive for DQA1*0101 and negative for HB*14, especially those with a normal thymus, have lower autoantibody titers than most other groups of patients.
The AChR epitope involved in DQA1*0101-positive patients could be created by the alternative splicing of the P3A exon. 31 This exon codes for 25 amino acids in the N-terminal extracellular domain that disrupt the main immunogenic region and impair the channel function of the AChR pentamer. 32 The previous report in a myasthenic patient of a T-cell clone that recognized an AChR epitope dependent on the P3A exon and presented by a DQA1*0101-encoded class II molecule is consistent with this hypothesis. 33 A similar mechanism has been proposed to explain the autoreactivity of SJL mice toward an epitope encoded by the DM20 splice variant of the proteolipid protein gene in induction of experimental allergic encephalomyelitis. 34 The association with the 8.1 ancestral HLA haplotype is likely to reflect a nonantigen specific dysregulation of the immune system, as this haplotype has been associated with susceptibility to different autoimmune diseases. 35 The TNFD marker belongs to the central region of HLA, which contains important candidate genes, notably lymphotoxin a and b and TNFa. These cytokines play an essential role in lymphoid organogenesis and notably in the formation of germinal centers, the cardinal feature of thymus hyperplasia. 36 An extensive characterization of the polymorphisms associated with the 8.1 ancestral haplotype is now in progress to refine the mapping of the loci involved in MG patients.
As a result of the polygenic control of MG, the combination of multiple loci leads to circumscribe most significant effects to subsets of patients of small size. Genetic heterogeneity, whether allelic or nonallelic, is a landmark of most human diseases. In this regard, we propose that differing associations between HLA class II loci and self-antigen polymorphisms might be present in patients who are negative for HB*14 and DQA1*0101. This would be consistent with the strikingly restricted heterogeneity of the human AChR epitopes recognized by T cells in transgenic mice expressing a single HLA class II molecule, as opposed the diversity of AChR epitopes observed in patients with varying HLA genotypes. 37 In summary, our findings demonstrate the interest of self-antigen encoding genes as candidates in genetic analyses of autoimmune traits. They show the existence of a significant genetic component underlying the variation of autoantibody titers in MG patients. They also provide a framework for future investigation of the cellular and molecular mechanisms of autoantibody expression and, hopefully, of MG pathogenesis.
Subjects and methods
Patients
A total of 480 unrelated Caucasoid patients were included in the study with their written informed consent and in keeping with the tenets of the Declaration of Helsinki. The patients were recruited in the three participating centers and their records were reviewed by one of us (PG, BE and CT). All patients fulfilled clinical and electromyographical diagnostic criteria of acquired generalized MG. 2, 3 Moreover, as the CHRNA1 gene was a candidate, only patients with confirmed positive titers of anti-AChR autoantibodies (40.6 nM) were investigated. Controls were Caucasians from various regions of France.
Serum sampling was not standardized relative to the initiation of immunosuppressive treatments. Anti-AChR autoantibody titers were precisely determined for all 480 cases by radioimmunoprecipitation of serial dilutions of sera as described, 6 with modifications, 13 using an antigen extract prepared from the AChR-expressing rhabdomyo- 38 In a given patient, the peak titer was considered for the analyses.
In principle, thymectomy was performed in MG patients with a thymoma or in those with an early onset of the disease, before 40 years of age, with positive antibody titers, and within a relatively short period of time after on the disease onset, less than 3 years. However, a number (n ¼ 36) of referred patients with an early disease-onset were not thymectomized.
Thymus histopathology was assessed as described elsewhere, 17 before the genotyping was conducted and therefore blindly to the entire genetic analysis. Thymus hyperplasia is defined by the presence of multiple lymphoid follicles with germinal centers in an otherwise normal organ. 39 , 40 The main clinical and biologic characteristics of these patients, including sex ratio, age at onset of disease, autoantibody peak titers, thymus histopathology in thymectomized patients, and associated autoimmune diseases, are summarized in Table 1 . Their correlations were described previously. 13 Microsatellite and HLA genotyping Genotyping of the TNFD and HB microsatellites was conducted as before, 18, 41 except that one of the oligonucleotide primers that was used for amplification was tagged with a fluorescent label. Amplification products were migrated on an ABI 373XL automated sequencer (Applied Biosystems). Alleles were determined with the Genescan and Genotyper software.
For HLA-DQA1 genotyping, exon II was PCR-amplified. Initially, PCR products were dot-blotted and hybridized with sequence-specific oligonucleotide probes, as described. 42 Subsequently, PCR products were typed by analysis of heteroduplexes. 43 Statistical analysis of data The influence of genetic markers and of thymus histopathology on autoantibody peak titers was tested by a multi-way analysis of variance (ANOVA), after normalization of the distribution of autoantibody titers by logarithmic transformation. Genetic markers were coded as binary variables, depending on the presence or absence of the associated allele. For thymus histopathology, four categories were considered, including thymus hyperplasia, thymoma, normal thymus, and nonthymectomized. Calculations of the F statistics, of the P-values and comparisons of the means were carried out with the ANOVA module of the Statistica 6.0 software (Statsoft Inc., Tulsa, OK, USA).
To test an interaction between HB*14 and HLA loci, the frequencies of marker alleles were also compared in patients and in control subjects. The control population consisted of 111 healthy Caucasian individuals recruited among blood donor volunteers. The three marker alleles, HB*14, DQA1*0101, and TNFD*1, were considered as binary random variables and the dependency of disease on these three covariates was tested with a logistic regression model. The fitted model resulted from ANOVA (see Results) and it included each of the three factors as first-order components, and an interaction term between HB*14 and DQA1*0101. Exact calculations of odds ratios and of P-values were made with the Logxact software v5.0 (Cytel Software Corp., Cambridge, MA, USA).
Transmission of HB microsatellite alleles from heterozygous parents to affected offspring was assessed by the TDT, 44 as implemented in the Genehunter software, 45 When scoring one-generation and simplex families, the TDT is a robust association test, insensitive to population structure, that is, it shows association that results primarily from linkage disequilibrium. Cases with one missing parent were included only when the genotyped parent and the proband were both distinct heterozygotes. 46 Exact probabilities were calculated using the binomial distribution, as indicated. 44 They were not corrected for the number of alleles tested because of prior knowledge of HB*14 association. Patients who were investigated in this family-based association study did not differ significantly from other patients with regard to the age at onset of the disease, the serum titers of antiAChR autoantibodies, and the sex ratio. The 98 trios investigated herein included 48 new families, compared to our previous study. 20 
